MK-677 vs Retatrutide for appetite
Short answer: For appetite, more users report improvement with Retatrutide — 73% of 84 reports, versus 62% of 152 for MK-677.
MK-677 has 0 meta-analyses and 15 randomized trials on PubMed; Retatrutide has 22 and 6.
Based on 692 reports about MK-677 and 446 about Retatrutide. Not medical advice.
| MK-677 Substance | Retatrutide Peptide | |
|---|---|---|
| User score | 45 | 71 |
| Verdict | Mixed | Mostly positive |
| Positive of reports that state an outcome | 41% | 76% |
| Reports | 692 | 446 |
| Research | BResearch: Moderate | BResearch: Moderate |
| Meta-analyses / RCTs | 0 / 15 | 22 / 6 |
| Mainly used for | ||
| Weight loss % reporting improvement | 63% (43) | 91% (222) |
| Appetite % reporting improvement | 62% (152) | 73% (84) |
| Focus % reporting improvement | 0% (3) | 83% (6) |
| Energy % reporting improvement | 39% (49) | 69% (75) |
| Sleep % reporting improvement | 78% (123) | 31% (26) |
| Anxiety % reporting improvement | 5% (21) | 40% (5) |
| Mood % reporting improvement | 59% (17) | 66% (32) |
| Performance % reporting improvement | 88% (68) | 82% (33) |
| Recovery % reporting improvement | 99% (81) | 100% (8) |
| Pain & inflammation % reporting improvement | 67% (18) | 78% (9) |
| Digestion % reporting improvement | 50% (2) | 46% (13) |
| Libido % reporting improvement | 25% (8) | 25% (12) |
| Hormones % reporting improvement | 41% (34) | 100% (13) |
| Blood sugar % reporting improvement | 5% (44) | 75% (4) |
| Heart & lipids % reporting improvement | 8% (12) | 37% (19) |
| Skin & hair % reporting improvement | 92% (24) | — |
| Common side effects | water retention, fatigue, hunger, stomach issues | nausea, fatigue, stomach issues, insomnia |
| Typical dose reported | 12.5 mg / before dinner | Not listed |
“From my own experience (also have suffered from poor sleep), i experienced a noticeable increase in sleep quality even with a low dose.”
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate